ZyVersa Therapeutics, Inc. (ZVSA) Fair Value 2026

ZVSA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

DANGER (63/100)

Quick Summary — As of 2026-08-27, ZyVersa Therapeutics, Inc. (ZVSA) trades at $0.10. QOC: 3.5/10. Value Trap Risk: 63/100 (DANGER). 0/13 models active.

Key Facts

Ticker
ZVSA
Price
$0.10
Quality Score
3.5/10
Value Trap Risk
63/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 63 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give ZVSA?

0 Intrinsic Value Models vs. Current Price ($0.10)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is ZyVersa Therapeutics, Inc. (ZVSA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ZyVersa Therapeutics, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About ZVSA?

0 of 13 models are currently active for ZVSA. See which stocks rank higher →

How Does ZVSA Rank in Biotechnology?

Among 620 Biotechnology stocks, ZVSA ranks #573 by Quality of Company score. CirclFi's QOC score of 3.5/10 evaluates 32 fundamental signals. A score of 3.5 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For ZyVersa Therapeutics, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is ZVSA a Value Trap?

CirclFi's Value Trap algorithm assigns ZVSA a score of 63/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for ZyVersa Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, ZyVersa Therapeutics, Inc. scores 3.5 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones. The elevated Value Trap score, however, warrants additional due diligence.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ZVSA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ZyVersa Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

XCURExicure, Inc.QOC 3.5KARDKardigan, Inc.QOC 3.5HURATuHURA Biosciences, Inc.QOC 3.5ADTXAditxt, Inc.QOC 3.4PCSAProcessa Pharmaceuticals, Inc.QOC 3.5KLRAKailera Therapeutics, Inc.QOC 3.4STROSutro Biopharma, Inc.QOC 6.3CRBUCaribou Biosciences, Inc.QOC 5.2SNTISenti Biosciences Holdings, Inc.QOC 4.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: XCUR · KARD · HURA · ADTX · PCSA · KLRA · STRO · CRBU · SNTI · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ZVSA?

4 companies across all industries closest to ZVSA’s Quality of Company score of 3.5/10.

REARare Earths Americas, Inc.QOC 3.5NUCLEagle Nuclear Energy Corp.QOC 3.5AADXApplied Aerospace & Defense, Inc.QOC 3.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: REA · NUCL · AADX · NVDA

Where Does ZVSA Sit in CirclFi's Biotechnology Rankings?

ZVSA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About ZyVersa Therapeutics, Inc.’s Valuation?

What is ZyVersa Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for ZyVersa Therapeutics, Inc. (ZVSA). The Quality of Company score is 3.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ZVSA overvalued or undervalued right now?

At $0.10, 0 of 0 active models suggest ZVSA may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits ZyVersa Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.5 mean for ZVSA?

ZyVersa Therapeutics, Inc.'s QOC of 3.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ZVSA?

CirclFi analyzes ZVSA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is ZVSA a value trap in 2026?

ZyVersa Therapeutics, Inc.'s Value Trap score is 63/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns ZyVersa Therapeutics, Inc. (ZVSA) a Quality of Company score of 3.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/ZVSA/ · Methodology
Primary sources for this ZVSA valuation
  • Financial statements: ZyVersa Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001859007) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ZVSA as of ; valuations recomputed .